HM
HZNP

Harvest Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Harvest Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-264,000
Closed -$30.5M – 75
2023
Q3 		$30.5M Buy
264,000
+160,200
+154% +$17.2M 15.89% 2
2023
Q2 		$10.7M Sell
103,800
-53,800
-34% -$5.68M 9.21% 3
2023
Q1 		$17.2M Buy
157,600
+51,000
+48% +$5.64M 12.99% 2
2022
Q4 		$12.1M Buy
+106,600
New +$8.85M 12.55% 1

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Harvest Management's HZNP Position: Q4 2023 in Review

Harvest Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 264,000 shares — an estimated $30.5M sold.

Harvest Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $30.5M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Harvest Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Harvest Management sold 264,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $30.5M.
  • Harvest Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Harvest Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $30.5M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Harvest Management's 13F filing for Q4 2023, filed 14 Feb 2024.